Recent advances for relapse prevention in psychotic disorders include new evidence on the efficacy of long-acting injectable antipsychotic therapy and the development of a computerized adaptive assessment tool for rapid evaluation of the severity of psychosis. A major challenge remains the underutilization of long-acting injectable antipsychotics, which is best addressed by education and shared decision-making. These topics were discussed by experts at WCP2021.
New insights into non-adherence to antipsychotic treatment
A major challenge in relapse prevention of psychosis is non-adherence with maintenance treatment
Which patients with schizophrenia are most likely to discontinue antipsychotic therapy, and does the formulation used — oral or long acting injectable (LAI) — play a role?
These questions were addressed by a study of 3343 first-episode psychosis patients in Finland who were followed up for a mean duration of 8 years (maximum 18 years).1
The results were presented by Professor Heidi Taipale, Kuopio, Finland:
- Discontinuation of antipsychotic treatment was most common after the first episode of psychosis and progressively decreased after each further episode (30% after first episode, 20% after second episode, 17% after third episode, 9% after tenth episode)
30% antipsychotic discontinuation rate was seen after first-episode psychosis in a study with a mean 8-year follow up
- Discontinuation was 67% less likely for patients treated with LAI vs oral antipsychotics
"The early phases of schizophrenia appear to be a critical period for interventions to improve treatment adherence", concluded Professor Taipale, "and this might be facilitated by greater use of LAI antipsychotics".
A new tool for rapid and reliable assessment of severity of psychosis
Discontinuation was 67% less likely for patients treated with LAI vs oral antipsychotics
"Assessment of severity of psychosis is necessary to evaluate response to treatment and provide optimal management of patients with schizophrenia",2 said Dr Daniel Guinart, Barcelona, Spain.
However, traditional pen and paper rating scales are not widely used due to their complexity and time constraints.2
A computerized adaptive testing (CAT) tool with the potential to provide rapid assessment to improve management of psychosis (CAT-psychosis) has therefore been developed and calibrated.3
LAI antipsychotics are underutilized despite the evidence showing they lower relapse rates
The development study, which involved 649 patients, and the validation study involving 160 patients and 40 healthy controls, were presented by Dr Daniel Guinart.
"The results show that CAT-psychosis assessed severity of psychosis rapidly and reliably", said Dr Guinart, "with median testing times of":
- "5 minutes for a clinician version"
- "1 minute 20 seconds for a patient self-report version"
What are the key messages for preventing relapse?
Discontinuing antipsychotic drug therapy increases the risk of relapse almost five times5
"Evidence supports the efficacy of antipsychotics in relapse prevention", said Professor John Kane, New York, NY. The number needed to treat to benefit is 3 for prevention of relapse at 1 year.4
In addition, discontinuing antipsychotic drug therapy increases the risk of relapse almost five times.5
As demonstrated by the study presented above by Professor Taipale, patients treated with LAI antipsychotics are 67% less likely to discontinue treatment that those taking oral antipsychotics.1 "But LAI formulations are largely underutilized", said Professor Kane.
Relapse rates can be improved by education and shared decision making
Reasons for the underutilization include negative clinicians’ attitudes towards LAI antipsychotics for patients with first-episode psychosis.6
"Education is therefore key to lower relapse rates", concluded Professor Kane,"together with shared decision making and a solution-based approach to logistic barriers".
WCP : World Congress of Psychiatry
LAI : long-acting injectables
CAT : Computerized Adaptive Testing
BE-NOTPR-0113, approval date : 1/2022
